Document Detail

Increased H-FABP concentrations in nonalcoholic fatty liver disease : Possible marker for subclinical myocardial damage and subclinical atherosclerosis.
MedLine Citation:
PMID:  23324907     Owner:  NLM     Status:  Publisher    
AIM: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder which is reported as the hepatic manifestation of metabolic syndrome with an increased risk of cardiovascular events. Patients with NAFLD are also at risk of future cardiac events independently of metabolic syndrome. The aim of this study was to examine serum concentrations of heart type fatty acid binding protein (H-FABP) in NAFLD and to investigate its correlations with metabolic parameters and subclinical atherosclerosis. PATIENTS AND METHODS: A total of 34 patients with NAFLD and 35 healthy subjects were enrolled in the study. NAFLD patients had elevated liver enzymes and steatosis graded on ultrasonography. Healthy subjects had normal liver enzymes and no steatosis on ultrasonography. H-FABP levels were measured using an enzyme linked immunosorbent assay (ELISA) method and correlations with metabolic parameters and subclinical atherosclerosis were examined. Subclinical atherosclerosis was determined with carotid artery intima-media thickness (CIMT) which was measured by high resolution B mode ultrasonography. RESULTS: H-FABP levels were elevated in patients with NAFLD (16.3 ± 4.0 ng/ml) when compared with healthy controls (13.8 ± 2.1 ng/ml; p  < 0.001). NAFLD patients had significantly higher CIMT than the controls had (0.64 ± 0.17 mm vs. 0.43 ± 0.14 mm, p = 0.009). The H-FABP concentrations were significantly positively correlated with body mass index (r = 0.255, p = 0.042), fasting blood glucose level (r = 0.300, p = 0.013), CIMT (r = 0.335, p = 0.043), and homeostasis model assessment-estimated insulin resistance (HOMA-IR; r = 0.156, p = 0.306). In multiple linear regression analysis, H-FABP levels were only independently associated with CIMT (p = 0.04) CONCLUSION: Serum H-FABP concentrations increase in patients with NAFLD. Our results may not only suggest that H-FABP is a marker of subclinical myocardial damage in patients with NAFLD but also of subclinical atherosclerosis, independent of metabolic syndrome and cardiac risk factors.
O Başar; E Akbal; S Köklü; Y Tuna; E Koçak; N Başar; D Tok; H Erbiş; M Senes
Related Documents :
24154027 - Comparison of hrct findings between chronic sarcoidosis and chronic hypersensitivity pn...
23936717 - Behçet's disease and intracardiac thrombosis: a report of three cases.
22958117 - Body fat distribution and risk factors for fibrosis in patients with alcoholic liver di...
25032707 - Brain mri co2 stress testing: a pilot study in patients with concussion.
727127 - Prolongation of cardiac conduction times by intravenous aprindine in man.
11522277 - Erythrocyte creatine as a marker of excessive erythrocyte destruction due to hypersplen...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-18
Journal Detail:
Title:  Herz     Volume:  -     ISSN:  1615-6692     ISO Abbreviation:  Herz     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7801231     Medline TA:  Herz     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Gastroenterology, Akdeniz University School of Medicine, Antalya, Turkey,
Vernacular Title:
Erhöhte H-FABP-Konzentrationen bei nichtalkoholbedingter Steatosis hepatis : Ein möglicher Marker für subklinische Myokardschädigung und subklinische Atherosklerose.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of coronary artery disease on in-hospital mortality in patients with aortic valve disease : R...
Next Document:  A new diagnostic method for woven coronary artery : Optical coherence tomography.